Group D streptococcal bacteremia, with emphasis on the incidence and presentation of infections due to Streptococcus bovis.
D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001770:Blood Bactericidal Activity / Q000187:drug effects; D002512:Cephalothin / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000209:etiology; D004698:Endocarditis, Subacute Bacterial / Q000209:etiology; D004917:Erythromycin / Q000494:pharmacology; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D009519:New York City; D010068:Oxacillin / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D018805:Sepsis / Q000188:drug therapy / Q000209:etiology*; D013290:Streptococcal Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D013291:Streptococcus / Q000187:drug effects / Q000302:isolation & purification*; D013307:Streptomycin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D010406:Penicillins; D002981:Clindamycin; D004917:Erythromycin; D014640:Vancomycin; D000667:Ampicillin; D013752:Tetracycline; D002512:Cephalothin; D010068:Oxacillin; D013307:Streptomycin